Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES

Young Hyuck Im, Bulent Karabulut, Keun Seok Lee, Byeong Woo Park, Aditya Adhav, Havva Yesil Cinkir, Hikmat Abdel-Razeq, Yuan Ching Chang, Sercan Aksoy, Seock Ah Im, Joon Jeong, Yeesoo Chae, James Bowles, Khemaies Slimane, Hongling Xue, Sung Bae Kim

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Background: This study was conducted to collect clinical safety, tolerability, and efficacy data with the use of everolimus (EVE) combined with exemestane (EXE) in patients with advanced breast cancer (ABC). Methods: The EVEREXES trial initiated in 2012, provided early access to the first dual blockade treatment with EVE + EXE in patients with HR+, HER2 − ABC in Asia and other emerging growth countries. Postmenopausal women with HR+, HER2 − ABC who had documented recurrence or progression, following a nonsteroidal aromatase inhibitor therapy, were treated with EVE (10 mg/day) + EXE (25 mg/day) orally. Results: A total of 235 patients received ≥ 1 dose of study medication. At the end of the study, all patients ceased the treatment. Disease progression (66.0%) was the primary reason of discontinuation. The most common AEs (≥ 20%) were stomatitis, decreased appetite, hyperglycemia, rash, aspartate aminotransferase increased, anemia, alanine aminotransferase increased, cough, and fatigue. No new safety concerns were identified in the current study. Median progression-free survival (PFS) in the Asian subset was similar to that of the overall population (9.3 months in both groups). Confirmed overall response rate (ORR) was achieved for 19.6% of the patients. Efficacy of EVE + EXE across subgroups (prior CT, line of treatment, and presence of visceral metastases) was maintained. Conclusion: The safety and efficacy results from EVEREXES trial are consistent to data previously reported in BOLERO-2. These results support that EVE + EXE could be a viable treatment option for the postmenopausal women with HR+, HER2 − ABC in Asian region.

Original languageEnglish
Pages (from-to)77-89
Number of pages13
JournalBreast Cancer Research and Treatment
Issue number1
Publication statusPublished - 2021 Jul

Bibliographical note

Funding Information:
The EVEREXES trial ( identifier NCT03176238). Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. The authors thank the patients who have enrolled in this study and their families as well as all the participating investigators and their site teams. The authors also thank Arundhati Halder, PhD, and Susmita Bhattacharjee, MSc. Biotechnology, of Novartis Healthcare Pvt Ltd (Hyderabad, India) for providing medical editorial assistance in accordance with the Good Publication Practice (GPP3) guidelines for the preparation of this manuscript.

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES'. Together they form a unique fingerprint.

Cite this